Journal of Vascular and Interventional Radiology最新文献

英文中文

Cover 封面

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/S1051-0443(25)00787-0

引用次数: 0

Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases 肿瘤吸收剂量、代谢反应和乳腺癌肝转移患者放射栓塞后的生存。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.045

Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD

Purpose

To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (⁹⁰Y) transarterial radioembolization (TARE).

Materials and Methods

Between August 2016 and August 2024, patients with BCLM who underwent ⁹⁰Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.

Results

Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).

Conclusions

Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.

目的：探讨经动脉放射栓塞（TARE）治疗乳腺癌肝转移（BCLM）患者肿瘤吸收剂量（TAD）与肿瘤反应及生存期的关系。方法与材料：回顾性分析2016年8月至2024年8月间行玻璃颗粒Y90-TARE治疗的BCLM患者。主要结局是总生存期（OS）和肝脏无进展生存期（hPFS）。次要终点为客观有效率。使用实体瘤正电子发射断层扫描反应标准（PERCIST）评估对治疗的反应。患者分为有反应组和无反应组。结果或发现：42例女性中有26例患者符合纳入标准，平均年龄为57.9±13.8岁。所有患者的中位OS和hPFS分别为6.1个月（IQR; 4.3-9.0个月）和4.2个月（IQR; 2.5-5.6个月）。应答者和无应答者的中位TAD分别为157 Gy和150 Gy （p=0.768）。应答者与无应答者的中位OS和hPFS分别为8.3个月（IQR; 5.5-14.8个月）和4.1个月（IQR; 3.1-6.3个月），而4.0个月（IQR; 2.5-4.5个月）和2.1个月（IQR; 1.3-2.7个月），分别为（p= 0.025和p= 0.210）。在145 Gy以上，TAD表现出显著的OS获益，但没有改变肝脏hPFS （p = 0.024和p = 0.397）。结论：在本研究中，影像学反应与OS有一定相关性，而TAD与反应无相关性。

{"title":"Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases","authors":"Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD","doi":"10.1016/j.jvir.2025.08.045","DOIUrl":"10.1016/j.jvir.2025.08.045","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</div></div><div><h3>Materials and Methods</h3><div>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</div></div><div><h3>Results</h3><div>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (<em>P</em> = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (<em>P</em> = .025 and <em>P</em> = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (<em>P</em> = .024 and <em>P</em> = .397, respectively).</div></div><div><h3>Conclusions</h3><div>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107833"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound Fusion in Interventional Radiology: A Practical Guide to Procedural Applications 介入放射学中的超声融合：程序应用的实用指南。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.016

Benjamin York MD , Bryce D. Beutler MD , Lenora M. Lewis MD , Ellen Y. Chang MD, MS , Ishan Shah BS , April Ballard MD , Brittany J. Kazmierski MD , Samantha S. Chau MD , Hisham Tchelepi MD

Ultrasound (US) fusion, defined as coregistration of cross-sectional images and real-time planar US, has emerged as a powerful tool to enhance the safety and accuracy of image-guided interventions. Computed tomography (CT), magnetic resonance (MR) imaging, and positron emission tomography (PET) can be integrated with conventional US using fusion navigation software, which is available from most major vendors. The US fusion technique enables precise intraprocedural localization of target lesions. The software is broadly accessible, intuitive to use, and suitable for implementation by both interventional and diagnostic radiologists in community and academic settings. In this narrative review, the authors present a comprehensive overview of US fusion–guided interventions, detailing the technical approach and providing case examples from a major teaching hospital.

超声融合被定义为横截面图像和实时平面超声的共同配准，已成为增强图像引导干预的安全性和准确性的有力工具。计算机断层扫描（CT）、磁共振成像（MRI）和正电子发射断层扫描（PET）可以使用融合导航软件与传统超声波集成，这些软件可以从大多数主要供应商那里获得。超声融合技术可以在术中精确定位目标病变。该软件易于访问，使用直观，适合社区和学术环境中的介入和诊断放射科医生实施。在这篇叙述性的综述中，我们提出了超声融合引导干预的全面概述，详细介绍了技术方法，并提供了来自一家大型教学医院的案例。

引用次数: 0

Abernethy Malformation Shunt Closure to Treat Hepatic Encephalopathy Mimicking Parkinson Disease 畸形分流关闭治疗模拟帕金森病肝性脑病。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.043

Rasmiranjan Padhi MBBS, MD , Arun Prasannan MBBS, MD , Virag Shethna MBBS, MD , Jagadeesan Dhanasekaran MBBS, MD , Shanmuga Sundaram Radhakrishnan MBBS, MD

引用次数: 0

Peripheral Vasculature Embolization with the Onyx Liquid Embolic System in a Swine Model 玛瑙液体栓塞系统在猪模型中的外周血管栓塞。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.032

Gary P. Siskin MD , Paul J. Rochon MD , Ripal Gandhi MD , Austin Cocciolone PhD , Andrew Winter PhD , Rahul S. Patel MD , Jafar Golzarian MD , Bulent Arslan MD

Purpose

To characterize the histologic and inflammatory changes that resulted from peripheral embolization using ethylene vinyl alcohol ([EVOH]; Onyx) in an animal model. This study also assessed the radiopacity of the Onyx after a 1-minute mixing time.

Materials and Methods

Embolization using EVOH alone or in combination with coils/plugs was performed on large-vessel, small-vessel, and very–small-vessel (3–5 mm, 1–3 mm, and <1 mm in diameter, respectively) targets in the peripheral vasculature of Yucatan miniature pigs. Multiple formulations of EVOH were used. Angiography at 1, 3, and 12 months was used to assess embolic migration and vessel occlusion. Pathological evaluations were performed to assess the biological response to Onyx-mediated embolization.

Results

Angiography demonstrated that the radiopacity of EVOH was sufficient for control during deployment in 98.2% of the procedures. Microcatheter removal was successful in all cases, and there was minimal migration of EVOH after delivery. Pathological findings indicated no significant tissue response or vessel trauma after embolization, and the occlusive material (consisting of EVOH, thrombus, and fibrotic tissue) evolved over time. The inflammatory response was minimal to mild, and vessel wall injury was observed in some cases. Complete to near-complete occlusion was achieved at every embolization site at the time of follow-up, although histologic evidence of recanalization was observed in 59.3% of the treated vessels.

Conclusions

The study demonstrated the effectiveness of EVOH as an embolic agent in the peripheral vascular system with adequate radiopacity, minimal adverse effects, and acceptable long-term histologic outcomes in a swine model.

目的：在动物模型中描述玛onyx （EVOH）外周栓塞引起的组织学和炎症变化。本研究还评估了混合时间1分钟后玛瑙的放射不透性。方法：分别对大血管、小血管和极小血管（3-5 mm、1-3 mm）进行EVOH单独或联合线圈/栓栓塞。结果：血管造影显示98.2%的手术中EVOH的放射不透性足以控制部署。所有病例均成功取出微导管，分娩后EVOH迁移最小。病理结果显示栓塞后没有明显的组织反应或血管损伤，并且闭塞物质（由EVOH、血栓和纤维化组织组成）随着时间的推移而演变。炎症反应轻微到轻微，在一些病例中观察到血管壁损伤。在随访时，每个栓塞部位都实现了完全或接近完全的闭塞，尽管在59.3%的治疗血管中观察到再通的组织学证据。结论：该研究在猪模型中证明了EVOH作为外周血管系统栓塞剂的有效性，具有足够的放射线透明度，最小的不良反应和可接受的长期组织学结果。

{"title":"Peripheral Vasculature Embolization with the Onyx Liquid Embolic System in a Swine Model","authors":"Gary P. Siskin MD , Paul J. Rochon MD , Ripal Gandhi MD , Austin Cocciolone PhD , Andrew Winter PhD , Rahul S. Patel MD , Jafar Golzarian MD , Bulent Arslan MD","doi":"10.1016/j.jvir.2025.08.032","DOIUrl":"10.1016/j.jvir.2025.08.032","url":null,"abstract":"<div><h3>Purpose</h3><div>To characterize the histologic and inflammatory changes that resulted from peripheral embolization using ethylene vinyl alcohol ([EVOH]; Onyx) in an animal model. This study also assessed the radiopacity of the Onyx after a 1-minute mixing time.</div></div><div><h3>Materials and Methods</h3><div>Embolization using EVOH alone or in combination with coils/plugs was performed on large-vessel, small-vessel, and very–small-vessel (3–5 mm, 1–3 mm, and <1 mm in diameter, respectively) targets in the peripheral vasculature of Yucatan miniature pigs. Multiple formulations of EVOH were used. Angiography at 1, 3, and 12 months was used to assess embolic migration and vessel occlusion. Pathological evaluations were performed to assess the biological response to Onyx-mediated embolization.</div></div><div><h3>Results</h3><div>Angiography demonstrated that the radiopacity of EVOH was sufficient for control during deployment in 98.2% of the procedures. Microcatheter removal was successful in all cases, and there was minimal migration of EVOH after delivery. Pathological findings indicated no significant tissue response or vessel trauma after embolization, and the occlusive material (consisting of EVOH, thrombus, and fibrotic tissue) evolved over time. The inflammatory response was minimal to mild, and vessel wall injury was observed in some cases. Complete to near-complete occlusion was achieved at every embolization site at the time of follow-up, although histologic evidence of recanalization was observed in 59.3% of the treated vessels.</div></div><div><h3>Conclusions</h3><div>The study demonstrated the effectiveness of EVOH as an embolic agent in the peripheral vascular system with adequate radiopacity, minimal adverse effects, and acceptable long-term histologic outcomes in a swine model.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107815"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Embolization of Roux-en-Y Limb Varices and Portal Vein/Rex Shunt Recanalization in Pediatric Liver Transplant Recipients with Gastrointestinal Bleeding 小儿肝移植术后消化道出血患者Roux-en-Y肢体静脉曲张栓塞及门静脉/Rex分流再通

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.011

Claudia Moya Ochoa MD , Eduardo Bravo Rius MD , Gloria González García MD , María Paz Muñoz Fernández MD , Álvaro Vega González MD , Leonardo Álvarez Aros MD

引用次数: 0

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion 经皮肝灌注治疗葡萄膜黑色素瘤肝转移。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.018

Siddharth A. Padia MD , Sachin Modi BSc, MBBS, FRCR, MD , Eric Wehrenberg-Klee MD , Robert D. Adamo MD , Altan Ahmed MD, MSc , Marlana Orloff MD , Hendrik J.F. Helmerhorst MD, PhD , Bartosz Chmielowski MD, PhD , Orhan S. Ozkan MD , Mark C. Burgmans MD, PhD , Gerd Grözinger MD , Robert J. Lewandowski MD , Venkatesh P. Krishnasamy MD

Uveal melanoma frequently metastasizes to the liver, with over 90% of metastatic cases involving hepatic spread. Despite systemic therapy advances, prognosis remains poor in hepatic-dominant disease. Percutaneous hepatic perfusion (PHP) with melphalan, now U.S. Food and Drug Administration (FDA)–approved via the Hepzato Kit, delivers high-dose chemotherapy directly to the liver while reducing systemic toxicity through extracorporeal filtration. This review outlines PHP’s rationale, technique, patient selection, and institutional requirements. Ideal candidates have multifocal, bilobar liver metastases and limited extrahepatic disease. PHP requires coordinated care across interventional radiology, anesthesia, perfusion, and pharmacy. Clinical data show encouraging survival and disease control with manageable hematologic toxicity and rapid recovery. Research into improved filtration, optimized dosing, and immunotherapy integration may further improve outcomes.

葡萄膜黑色素瘤（UM）经常转移到肝脏，超过90%的转移病例涉及肝脏扩散。尽管全身治疗取得进展，但肝显性疾病的预后仍然很差。经皮肝灌注（PHP）使用melphalan，目前已通过Hepzato Kit获得fda批准，可直接向肝脏提供高剂量化疗，同时通过体外过滤降低全身毒性。这篇综述概述了PHP的基本原理、技术、患者选择和机构要求。理想的候选人有多灶性、双叶性肝转移和有限的肝外疾病。PHP需要介入放射学、麻醉、灌注和药学的协调护理。临床数据显示令人鼓舞的生存和疾病控制与可控的血液毒性和快速恢复。改进过滤、优化剂量和免疫治疗整合的研究可能会进一步改善结果。

{"title":"Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion","authors":"Siddharth A. Padia MD , Sachin Modi BSc, MBBS, FRCR, MD , Eric Wehrenberg-Klee MD , Robert D. Adamo MD , Altan Ahmed MD, MSc , Marlana Orloff MD , Hendrik J.F. Helmerhorst MD, PhD , Bartosz Chmielowski MD, PhD , Orhan S. Ozkan MD , Mark C. Burgmans MD, PhD , Gerd Grözinger MD , Robert J. Lewandowski MD , Venkatesh P. Krishnasamy MD","doi":"10.1016/j.jvir.2025.10.018","DOIUrl":"10.1016/j.jvir.2025.10.018","url":null,"abstract":"<div><div>Uveal melanoma frequently metastasizes to the liver, with over 90% of metastatic cases involving hepatic spread. Despite systemic therapy advances, prognosis remains poor in hepatic-dominant disease. Percutaneous hepatic perfusion (PHP) with melphalan, now U.S. Food and Drug Administration (FDA)–approved via the Hepzato Kit, delivers high-dose chemotherapy directly to the liver while reducing systemic toxicity through extracorporeal filtration. This review outlines PHP’s rationale, technique, patient selection, and institutional requirements. Ideal candidates have multifocal, bilobar liver metastases and limited extrahepatic disease. PHP requires coordinated care across interventional radiology, anesthesia, perfusion, and pharmacy. Clinical data show encouraging survival and disease control with manageable hematologic toxicity and rapid recovery. Research into improved filtration, optimized dosing, and immunotherapy integration may further improve outcomes.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107887"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145370520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-Expanding Interwoven Nitinol Wire Stents for Treatment of Common Iliac Artery Stent Collapse 超级支架在髂总动脉支架塌陷中成功的再介入治疗。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.024

Kensuke Uotani MD, Yutaka Koide MD, Yutaro Okamoto MD, Takuya Takahashi MD, Mai Takahashi MD, Ryota Kawasaki MD

引用次数: 0

Crossword Puzzle: Answer Key 填字游戏：回答关键

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.107913

引用次数: 0

Feasibility and Effectiveness of Yttrium-90 Radioembolization in Normal Lung Parenchyma: A Preclinical Study in Rabbits with Pathological Correlation to Absorbed Dose 钇-90放射栓塞正常肺实质的可行性及疗效：与吸收剂量病理相关的兔临床前研究。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.044

Ioannis Spyridonidis MD , Marios Platon Dimopoulos MD, MSc, PhD(c) , Pinelopi Bosgana MD , Trifon Spyridonidis MD , Theodoros Skouras MD , Michalis Theofanis MD , Christos Papageorgiou MD , Nikolaos Giannikas MD, MSc , Panagiotis M. Kitrou MD, MSc, PhD , Konstantinos Katsanos MD, MSc, PhD , Dimitrios Karnabatidis MD, PhD

This study investigated the effects of yttrium-90 (⁹⁰Y) radioembolization in 8 rabbits, focusing on delivery accuracy, dosimetry, and pathological outcomes. ⁹⁰Y was successfully delivered angiographically targeted via the pulmonary lower basal segmental arteries to all rabbits, with confirmation via positron emission tomography (PET)/computed tomography (CT) imaging and a lung target median of the mean dose of 132.1 Gy (range, 11.2–262.3 Gy). Pathological analysis in all surviving subjects revealed complete necrosis of the irradiated segments, with associated inflammation in adjacent nonirradiated tissue. Radiological follow-up with CT scan showed triangular fibrosis in 6 rabbits at 1 month, progressing to fibrosis at 3 months. Dosimetry analysis confirmed dose distribution to the targeted lung regions. Of 8 rabbits, 1 died intraprocedurally, and another died 1.5 weeks after the procedure for unknown reasons. The remaining rabbits had no severe adverse events, with 1 case of pleural effusion resolving with no intervention at 3 months. The study demonstrated the feasibility of ⁹⁰Y delivery to the lungs.

本研究在8只家兔中研究了钇-90 （Y90）放射栓塞的效果，重点研究了传递准确性、剂量学和病理结果。所有家兔均成功通过肺下基段动脉血管造影靶向给予Y90， PET/CT成像证实，肺靶中位平均剂量132.1Gy（范围11.2-262.3Gy）。所有存活受试者的病理分析显示辐照节段完全坏死，邻近未辐照组织伴有相关炎症。放射学随访和ct扫描显示6只兔在1个月时呈三角形纤维化，在3个月时进展为纤维化。剂量学分析证实剂量分布到靶肺区域。在8只兔子中，一只在手术中死亡，另一只在手术后1.5周死亡，原因不明。其余兔无并发症，1例胸腔积液在3个月时无干预解决。该研究证明了将Y90输送到肺部的可行性。

{"title":"Feasibility and Effectiveness of Yttrium-90 Radioembolization in Normal Lung Parenchyma: A Preclinical Study in Rabbits with Pathological Correlation to Absorbed Dose","authors":"Ioannis Spyridonidis MD , Marios Platon Dimopoulos MD, MSc, PhD(c) , Pinelopi Bosgana MD , Trifon Spyridonidis MD , Theodoros Skouras MD , Michalis Theofanis MD , Christos Papageorgiou MD , Nikolaos Giannikas MD, MSc , Panagiotis M. Kitrou MD, MSc, PhD , Konstantinos Katsanos MD, MSc, PhD , Dimitrios Karnabatidis MD, PhD","doi":"10.1016/j.jvir.2025.08.044","DOIUrl":"10.1016/j.jvir.2025.08.044","url":null,"abstract":"<div><div>This study investigated the effects of yttrium-90 (<sup>90</sup>Y) radioembolization in 8 rabbits, focusing on delivery accuracy, dosimetry, and pathological outcomes. <sup>90</sup>Y was successfully delivered angiographically targeted via the pulmonary lower basal segmental arteries to all rabbits, with confirmation via positron emission tomography (PET)/computed tomography (CT) imaging and a lung target median of the mean dose of 132.1 Gy (range, 11.2–262.3 Gy). Pathological analysis in all surviving subjects revealed complete necrosis of the irradiated segments, with associated inflammation in adjacent nonirradiated tissue. Radiological follow-up with CT scan showed triangular fibrosis in 6 rabbits at 1 month, progressing to fibrosis at 3 months. Dosimetry analysis confirmed dose distribution to the targeted lung regions. Of 8 rabbits, 1 died intraprocedurally, and another died 1.5 weeks after the procedure for unknown reasons. The remaining rabbits had no severe adverse events, with 1 case of pleural effusion resolving with no intervention at 3 months. The study demonstrated the feasibility of <sup>90</sup>Y delivery to the lungs.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107827"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Vascular and Interventional Radiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀